{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011443","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.546406+00:00","generated_at":"2026-06-04T07:26:34.983813+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Provectus licenses University of Miami's rose bengal PDAT for eye infections; will form spinout","bullets":["Exclusive worldwide license for photodynamic antimicrobial therapy (PDAT) using rose bengal sodium to treat bacterial, fungal, and acanthamoeba keratitis.","Upfront fee of $10k; 10% royalty on net sales; annual maintenance fees of $1k (years 1-4) then $10k; development milestones up to $55k.","Company to form a majority-owned NewCo within one year; University gets 5% equity and up to 30% of sublicense income depending on clinical phase.","Technology supported by two international randomized clinical trials (NCT05110001, NCT06271772) for acanthamoeba/fungal and bacterial keratitis.","Provectus will supply pharmaceutical-grade rose bengal sodium to NewCo exclusively."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011443","json":"https://secwatch.observer/filing/0001493152-24-011443.json","markdown":"https://secwatch.observer/filing/0001493152-24-011443.md","text":"https://secwatch.observer/filing/0001493152-24-011443.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315224011443/0001493152-24-011443-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315224011443/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:26:34.983813+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a7710c04f563731c761aa3232156b13ff1264e03","claim":"PROVECTUS BIOPHARMACEUTICALS, INC. entered into Exclusive License Agreement with University of Miami (effective 2024-03-21).","evidence_excerpt":"On March 21, 2024, Provectus Biopharmaceuticals, Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with the University of Miami (the “University”) for the license and development of the University’s intellectual property related to photodynamic antimicrobial therapy in ophthalmology.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/315545/000149315224011443/0001493152-24-011443-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"University of Miami"},{"label":"Effective","value":"2024-03-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}